L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study.

BACKGROUND L-Arginine is the precursor of endogenous nitric oxide (NO), which is a potent vasodilator acting via the intracellular second-messenger cGMP. In healthy humans, L-arginine induces peripheral vasodilation and inhibits platelet aggregation due to an increased NO production. Prostaglandin E1 (PGE1) induces peripheral vasodilation via stimulating prostacyclin receptors. METHODS AND RESULTS We investigated the effects of one intravenous infusion of L-arginine (30 g, 60 minutes) or PGE1 (40 microgram, 60 minutes) versus those of placebo (150 mL 0.9% saline, 60 minutes) on blood pressure, peripheral hemodynamics, and urinary NO3- and cGMP excretion rates in patients with critical limb ischemia (peripheral arterial occlusive disease stages Fontaine III or IV). Blood flow in the femoral artery was significantly increased by L-arginine (+42.3 +/- 7.9%, P<.05) and by PGE1 (+31.0 +/- 10.2%, P<.05) but not by placebo (+4.3 +/- 13.0%, P=NS). Urinary NO3- excretion increased by 131.8 +/- 39.5% after L-arginine (P<.05) but only by 32.3 +/- 17.2% after PGE1 (P=NS). Urinary cGMP excretion increased by 198.7 +/- 84.9% after L-arginine (P<.05) and by 94.2 +/- 58.8% after PGE1 (P=NS). Both urinary index metabolites were unchanged by placebo. CONCLUSIONS We conclude that intravenous L-arginine induces NO-dependent peripheral vasodilation in patients with critical limb ischemia. These effects are paralleled by increased urinary NO3- and cGMP excretion, indicating an enhanced systemic NO production. Increased urinary NO3- excretion may be a sum effect of NO synthase substrate provision (L-arginine) and increased shear stress (PGE1 and L-arginine).

[1]  R. Brandes,et al.  Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. , 1995, Atherosclerosis.

[2]  S. Bode-Böger,et al.  Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. , 1994, Journal of chromatography. B, Biomedical applications.

[3]  S. Bode-Böger,et al.  Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats. , 1994, Cardiovascular research.

[4]  A. Quyyumi,et al.  Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. , 1994, Journal of the American College of Cardiology.

[5]  Yuan‐jian Li,et al.  Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. , 1994, Life sciences.

[6]  S. Lundin,et al.  Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. , 1993, Circulation research.

[7]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[8]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[9]  S. Eguchi,et al.  l‐ARGININE INFUSION INDUCES HYPOTENSION AND DIURESIS/NATRIURESIS WITH CONCOMITANT INCREASED URINARY EXCRETION OF NITRITE/NITRATE AND CYCLIC GMP IN HUMANS , 1992, Clinical and experimental pharmacology & physiology.

[10]  S. Moncada,et al.  Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis , 1992, Journal of cardiovascular pharmacology.

[11]  J. Frölich,et al.  Determination of endothelium-derived nitrite/nitrate by gas chromatography/tandem mass spectrometry using (15N)NaNO2 as internal standard. , 1992, Biological mass spectrometry.

[12]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[13]  F. Murad,et al.  Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Saruta,et al.  L-arginine-induced hypotension , 1991, The Lancet.

[15]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[16]  J. Cooke,et al.  L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. , 1990, Circulation research.

[17]  J. Loscalzo,et al.  Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. , 1990, The Journal of clinical investigation.

[18]  S. Moncada,et al.  Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. , 1990, The American journal of physiology.

[19]  L. Ignarro.  Biosynthesis and metabolism of endothelium-derived nitric oxide. , 1990, Annual review of pharmacology and toxicology.

[20]  S. Tannenbaum,et al.  L-arginine is a precursor for nitrate biosynthesis in humans. , 1989, Biochemical and biophysical research communications.

[21]  P. Ganz,et al.  Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. , 1989, Circulation.

[22]  D. Harrison,et al.  Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: implications for altered autocrine and paracrine functions of EDRF. , 1989, Blood vessels.

[23]  G. FitzGerald,et al.  Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. , 1988, Thrombosis research.

[24]  U. Förstermann,et al.  Selective Attenuation of Endothelium‐Mediated Vasodilation in Atherosclerotic Human Coronary Arteries , 1988, Circulation research.

[25]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[26]  A. Creutzig,et al.  Intermittent intra-arterial prostaglandin E1 therapy of severe claudication. , 1987, VASA. Supplementum.

[27]  A. Creutzig,et al.  Effects of intra‐arterial prostaglandin E1 in patients with peripheral arterial occlusive disease , 1986, European journal of clinical investigation.

[28]  F. Murad,et al.  Cyclic guanosine monophosphate as a mediator of vasodilation. , 1986, The Journal of clinical investigation.

[29]  R Busse,et al.  Crucial role of endothelium in the vasodilator response to increased flow in vivo. , 1986, Hypertension.

[30]  R. Gill.  Measurement of blood flow by ultrasound: accuracy and sources of error. , 1985, Ultrasound in medicine & biology.

[31]  A. Serradimigni,et al.  Alteration in Prostacyclin and Prostaglandin E2 Production: Correlation with Changes in Human Aortic Atherosclerotic Disease , 1984, Arteriosclerosis.

[32]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[33]  A. Olsson,et al.  INTRAVENOUS PROSTAGLANDIN E1 IN SEVERE PERIPHERAL VASCULAR DISEASE , 1976, The Lancet.

[34]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[35]  D. London,et al.  The measurement of arginine in plasma. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[36]  W. Sterling Edwards,et al.  Blood Vessels , 1959 .